Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
How do you counsel patients who are candidates for a clinical trial regarding their options?
I typically discuss the option with patients as early as possible in their diagnosis, and explain that at some point during their treatment they may become a candidate for a clinical trial. I discuss resources to look into clinical trials and what they mean for patients. We discuss patient website r...
How do you approach multiply recurrent early-stage oral tongue SCC despite multiple resections?
Surgery and postop RT.
Would you consider XRT for relapsed seminoma in the retroperitoneum, pelvis, and mediastinum with good response after chemo, but with poor kidney function?
If the patient has responded to chemo and has residual mass, most likely it is benign with fibrosis and PET scan in this setting can help as has very high negative predictive value.
What is your practice for the use of bolus in patients with breast cancer who had mastectomy and expander placement?
We still treat with bolus on these patients (0.3cm QOD for first 10 days), however, a retrospective review was published in the Red Journal recently that is interesting.In this review, >1500 patients were treated with bolus, 318 had no bolus (basically, half of the reconstructed patients). There was...
What dose constraints do you use for the stomach in conventionally fractionated definitive chemoradiation for a large LLL primary tumor?
I would aim to keep point max to the stomach under 50.4 Gy. This can be challenging for sure if nearby the tumor. I would use the same constraints if patient had a hiatal hernia. Moreover, I would have the patient NPO prior to sim and every treatment as that may help create separation between the st...
What is the evidence/rationale for not treating neuroblastoma metastatic sites which are MIBG negative after induction chemo?
A clinically meaningful number of high-risk neuroblastoma patients are curable, which in part justifies metastasis-directed local therapy. It can be difficult though to balance the toxicity of multi-site irradiation with maximum control of sites of metastatic disease. Metastases that persist after i...
What is the volume and dose for a rhabdo bone met showing complete response to chemo?
On ARST1431, the GTV2 for a bone met in CR should be defined as the residual bone abnormality as seen by CT/MRI at the time of RT planning. SBRT to bony metastases is optional on 1431 and the decision may vary based on patient age and other factors. On the upcoming high risk protocol, where SBRT to ...
What dose do you treat the involved lymph node chain to in definitive radiation for rhabdomyosarcoma?
In our trials, we have used 36 Gy for microscopic nodal disease treatment (either the CTV surrounding gross lymph node involvement or for nodal regions where resection has been performed - e.g. paraaortic LNs in paratesticular primary disease). The extent of this 36Gy treatment volume in the H&N reg...
Can hydrogel, SpaceOAR, placed interstitially for prostate cancer embolize to the lung?
I doubt that this could happen as the Precursor and Accelerator solidify rapidly. Moreover, when injected between the rectum and prostate as indicated, there would not be a clear vascular route for it to reach the lung. However, if the Precursor alone containing undissolved polyethylene glycol (PEG)...
Would you recommend radiation to oligometastatic boney site for an otherwise pure seminoma who had a CR to BEP x4?
I would first suggest getting a biopsy of the bone lesion. It can be difficult to assess response in a bone met. Solitary bone met is extremely rare in germ cell cancers. If there is disease that did not respond to 4xBEP at a metastatic site, this suggests that the patient harbors micometastic dis...